STAT+: Roche to buy PathAI for $750 million

Roche has signed a deal to acquire PathAI for $750 million upfront, with potential additional earnings of $300 million. The acquisition aims to accelerate Roche's use of artificial intelligence in pathology diagnostics. The agreement is expected to close in the second half of the year.